"Pulmo BioTech Inc. (BULLETIN BOARD: PLMO) announced that it has increased its stake in PulmoScience Inc. by ten per cent, taking its total holdings to 61 per cent in this company which owns a molecular imaging diagnostic technique for pulmonary related medical conditions.
Pulmo BioTech CEO Garry McCann said, "We are confident the molecular imaging technology, developed and owned by PulmoScience, will dominate the market for the diagnosis of pulmonary embolism and pulmonary hypertension, and as such, with the company moving towards Regulatory Approval for Phase I Human Trials, we felt that this was the right time to increase our stake in the company."
PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external gamma camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician."
